Compare NYXH & INGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NYXH | INGN |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.9M | 177.1M |
| IPO Year | 2021 | 2013 |
| Metric | NYXH | INGN |
|---|---|---|
| Price | $1.60 | $6.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $9.33 | ★ $11.25 |
| AVG Volume (30 Days) | 217.1K | ★ 221.8K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $348,668,000.00 |
| Revenue This Year | $213.98 | $8.03 |
| Revenue Next Year | $126.25 | $7.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.86 |
| 52 Week Low | $1.26 | $5.34 |
| 52 Week High | $8.59 | $9.13 |
| Indicator | NYXH | INGN |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 45.63 |
| Support Level | $1.26 | $6.00 |
| Resistance Level | $1.70 | $6.72 |
| Average True Range (ATR) | 0.11 | 0.26 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 18.40 | 18.07 |
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.